What is the recommended treatment for a patient with moderate to severe psoriasis?

Treatment for Psoriasis

For moderate to severe psoriasis, initiate biologic therapy with adalimumab (80 mg initial dose, then 40 mg subcutaneously every 2 weeks starting one week later) as first-line systemic treatment, combined with topical calcipotriene/betamethasone dipropionate once daily for residual plaques. 1, 2, 3

---

Disease Severity Classification and Treatment Selection

Mild psoriasis (<5% body surface area):

• Start with combination topical therapy using calcipotriene plus betamethasone dipropionate applied once daily for 4 weeks, which achieves 69-74% clear or almost clear status compared to 27% with vehicle control 1, 4
• This combination provides superior efficacy to monotherapy through complementary mechanisms: vitamin D analogs inhibit epidermal hyperproliferation while corticosteroids suppress inflammatory cytokines 5
• Long-term use up to 52 weeks is safe with no serious adverse events reported 4

Moderate to severe psoriasis (≥5% body surface area):

• Biologic therapy is mandatory as first-line systemic treatment 1, 2
• Adalimumab achieves PASI 75 in 71% of patients at week 16 versus 7% with placebo 1
• Alternative biologics include infliximab (80% PASI 75 response) dosed at 5 mg/kg IV at weeks 0,2,6, then every 8 weeks 1
• Etanercept 50 mg subcutaneously twice weekly for 12 weeks, then once weekly, achieves PASI 75 in 48% at week 12 1

---

Optimal Treatment Regimens by Severity

For Mild Disease: Topical Therapy Algorithm

Initial phase (weeks 1-4):

• Apply calcipotriene/betamethasone dipropionate combination product once daily 1, 4
• This single-product approach maximizes compliance and achieves maximal improvement within 4 weeks 1

Maintenance phase (after week 4):

• Apply vitamin D analogues twice daily on weekdays combined with high-potency topical corticosteroids twice daily on weekends 1
• Alternative: morning high-potency topical corticosteroid with evening topical vitamin D analogue 1
• This steroid-sparing approach reduces adverse effects while maintaining efficacy 4

For Moderate to Severe Disease: Biologic Plus Adjunctive Topical Therapy

Primary systemic therapy:

• Adalimumab: 80 mg initial dose, followed by 40 mg one week later, then 40 mg every 2 weeks thereafter 1, 3
• Continue biologic therapy indefinitely for sustained disease control 2
• Never interrupt biologic therapy, as this increases antibody formation, infusion reactions, and reduces efficacy 4

Mandatory adjunctive topical therapy:

• Add high-potency topical corticosteroid to standard-dose etanercept or adalimumab for 12-16 weeks to accelerate clearance (Grade A recommendation) 1
• Add calcipotriene/betamethasone dipropionate to biologics to enhance efficacy and target residual plaques (Grade A-B recommendation) 1, 2
• All topical corticosteroids can be combined with any biologic 1

---

Site-Specific Treatment Approaches

Scalp psoriasis:

• First-line: calcipotriene foam or calcipotriene plus betamethasone dipropionate gel for 4-12 weeks 1, 2, 4
• Cost-effective alternative: generic clobetasol propionate 0.05% solution applied twice daily 1

Facial/intertriginous psoriasis:

• Use tacalcitol ointment or calcipotriene combined with hydrocortisone for 8 weeks 2, 4
• Avoid ultrapotent corticosteroids on the face due to atrophy risk 2

Nail psoriasis:

• Apply topical vitamin D analogs combined with betamethasone dipropionate to reduce nail thickness, hyperkeratosis, onycholysis, and pain 4

Palmoplantar psoriasis:

• Initial treatment: topical maxacalcitol ointment 4
• For palmoplantar pustular psoriasis: acitretin 4

---

Special Clinical Situations

Psoriatic arthritis (any severity):

• Adalimumab is mandatory as monotherapy regardless of skin body surface area involvement, as it treats both skin and joint symptoms and inhibits radiographic joint damage 1, 2
• Infliximab is an alternative that also inhibits radiographically detected joint damage 1

Erythrodermic psoriasis:

• Cyclosporine 3-5 mg/kg/day is the preferred initial treatment due to rapid onset of action 2

Symptomatic psoriasis with pain, bleeding, or itching:

• Consider systemic or phototherapy even for limited body surface area involvement 1

Women of childbearing potential:

• Avoid acitretin due to teratogenic effects 2

---

Combination Strategies with Conventional Systemic Agents

When biologics are not appropriate or available:

• Add topical calcipotriene to standard-dose methotrexate (Grade A recommendation) 1
• Add calcipotriene/betamethasone dipropionate ointment to low-dose cyclosporine 2 mg/kg/day 1
• Add calcipotriene to standard-dose acitretin (Grade A recommendation) 1

---

Critical Safety Considerations and Monitoring

Before initiating biologics:

• Perform test for latent tuberculosis; if positive, start TB treatment prior to starting adalimumab 3
• Monitor all patients for active TB during treatment, even if initial latent TB test is negative 3
• Screen for serious infections, as adalimumab increases risk of serious infections leading to hospitalization or death 3

During treatment:

• Discontinue adalimumab if patient develops serious infection or sepsis 3
• Monitor for malignancies, including lymphoma and hepatosplenic T-cell lymphoma, particularly in adolescent and young adult patients 3
• Watch for anaphylaxis or serious hypersensitivity reactions 3
• Regular examinations for skin atrophy with topical corticosteroid use 4

Inadequate response:

• If inadequate response after 12-16 weeks of biologic therapy, switch to an alternative biologic rather than adding a second biologic 2
• For ulcerative colitis indication: discontinue if no clinical remission by 8 weeks (Day 57) 3

---

Common Pitfalls to Avoid

Do not use topical therapy alone for moderate to severe psoriasis:

• This is inadequate and delays appropriate systemic treatment 4
• Topical therapy should only be used as adjunctive therapy in moderate to severe disease 2

Do not combine salicylic acid with calcipotriene:

• The acid pH inactivates calcipotriene and reduces effectiveness 1

Do not assume treatment failure is "tachyphylaxis":

• Perceived treatment failure with topical corticosteroids is usually due to poor adherence, not receptor down-regulation 4

Do not use high-potency corticosteroids on face/intertriginous areas:

• Use lower potency agents like mometasone furoate in these sensitive areas 4

Do not interrupt biologic therapy:

• Interrupted therapy increases antibody formation, infusion reactions, and poorer disease control 4